scholarly journals Vaccines’ Candidates Against SARS-CoV-2

2020 ◽  
Vol 3 (2) ◽  
pp. 249-266
Author(s):  
ISI-SENAI-CIMATEC Group ◽  
Development and Innovation Laboratory of Butantan Institute
Keyword(s):  
New England ◽  
Viral Vector ◽  
Clinical Investigation ◽  
Meta Analysis ◽  
Phase 1 ◽  
World Health ◽  
Phase 2 ◽  
Medical Subject Headings ◽  
Vaccine Platform ◽  
Novel Coronavirus

Scientists, health organizations, and pharmaceutical companies are making a large global effort to develop vaccines against SARS-CoV-2, the virus of COVID-19 since the outbreak began. Until now, we have more than 150 candidates. However, 19 vaccine candidates have entered clinical trials in phase 2 and 3 trials (31 July 2020). In this article we aimed to present the platforms for COVID-19 vaccine, the types of vaccines (live, attenuated, inactivated, DNA/RNA, proteins subunits, viral vector), the antigen selection, adjuvants, and we focused on the phase 2/3 trial vaccines at this point (Sinopharm, Coronavac, Moderna, Oxford, Biontech). We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We reviewed 216 articles and used 106 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, vaccine, platform, antigen, subunit, live and attenuated vaccine, RNA vaccine, live vaccine, inactivated vaccine, types of vaccines, adjuvants, replication, viral vector, phase 1-3, trial, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that although vaccines have shown safety in phase 1 and efficacy in phase 2 and the beginning of phase 3 is starting, the most renowned scientists believe that a vaccine will be available only in the middle of next year.  

scholarly journals History of Pandemics and COVID-19: What We are Learning from this Pandemic to Be Prepared for the Next One

2020 ◽  
Vol 3 (1) ◽  
pp. 12-27
Author(s):  
Luciana Knop ◽  
Roberto Badaró
Keyword(s):  
New England ◽  
Clinical Investigation ◽  
Meta Analysis ◽  
World Health ◽  
Medical Subject Headings ◽  
Journal Citation Reports ◽  
The Social ◽  
History Of ◽  
Novel Coronavirus ◽  
Health Organization

Since the beginning of human history, the pathogens affect the humankind. The emerge of the new outbreak of coronavirus-19 (COVID-19) is not new in the history of plagues. However, this pandemic has a huge difference from the others due to its ability to affect worldwide at the same time, which brings new perspectives to our future. In this review, we listed some of the worst epidemics and pandemics of human civilization and the new outbreak, listing the pathogens, the spread, and the consequences for mankind. Our search included articles in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Exerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We reviewed 192 articles and used 94 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, COVID, n-SARS-2, COVID-19, corona virus, coronaviruses, history of pandemics and epidemics, pathogens, plagues, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that this pandemic will change the social and economic order, as well as it is the first that affects us quickly. So, the experience of COVID-19 could teach us how to be prepared for other outbreaks in the future.

scholarly journals The Epidemiology, Transmissions and Risk Factors of SARS-CoV-2

2020 ◽  
Vol 3 (1) ◽  
pp. 28-43
Author(s):  
Roberto Badaró ◽  
Bruna Aparecida Souza Machado ◽  
Milena Soares ◽  
Luciana Knop
Keyword(s):  
Risk Factors ◽  
Incubation Period ◽  
Clinical Investigation ◽  
Meta Analysis ◽  
Case Fatality ◽  
Epidemiological Data ◽  
Mitigation Strategies ◽  
World Health ◽  
Medical Subject Headings ◽  
Novel Coronavirus

The outbreak of a novel coronavirus (SARS-CoV-2) and associated COVID-19 disease in late December 2019 has led to a global pandemic, spreading very quickly and causing a more than 500,000 deaths in less than six monhs of the ourbreak. The incidence differs by country and depends on many agents, such as population density, demography, the amount of testing people and reporting, and actions of mitigation strategies, provisions of sanitary and education of the society. In this article, we presented the current studies about the epidemiology of COVID-19, including the transmission routes of the SARS-CoV-2, the incubation period, the reproduction number (R0), the case fatality risks (CFR), comorbidities and measures prevention against COVID-19. We searched the articles in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Exerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews and original articles in this order. We reviewed 235 articles and used 131 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-Sars-2, COVID-19, corona virus, coronaviruses, epodemiology of COVID-19, risk factors, viral spreading, transmissions, routes, animals incubation, period, RO, CFR, comorbidities, prevention, with the tools MeSH (Medical Subject Headings), AND, OR, and characters [,“,; /., to ensure the best review topics. We concluded that the epidemiological data is very important to know the transmission risks rate, purpose public political policies of mitigating the disease, protect the vulnerable population. Also, it is important reconsider the legislation about wild animals, the potential intermediate host(s) of various viruses, as well as the conditions of live for animals for human comsuption to prevent future outbreaks.

scholarly journals Therapies Against COVID-19: a Running to a Treatment

2020 ◽  
Vol 3 (2) ◽  
pp. 184-248
Author(s):  
ISI-SENAI-CIMATEC Group ◽  
Development and Innovation Laboratory of Butantan Institute
Keyword(s):  
Treatment Guidelines ◽  
Clinical Investigation ◽  
Combined Therapy ◽  
Alternative Therapies ◽  
World Health ◽  
Medical Subject Headings ◽  
Antiinflammatory Drugs ◽  
Cell Receptors ◽  
Novel Coronavirus

There is no specific drug or therapy against COVID-19. Since the beginning of the pandemic, scientists are running to discover a drug or therapy that can treat the disease. What we found until now are a combined drug and therapies that can mitigate the effects of the disease in the human body and how to manage the patient better. In this article, we tried to join the new discoveries and presented the drugs and therapies and their mechanisms to combat the SARS-CoV-2. We showed the immunomodulators, parasiticides, antiviral drugs (focused on Remdesivir), antimalarial drugs, anti-cytokine drugs focused on the role of IL-6, Reumathological drugs, inhibitors of cell-receptors, antiinflammatory drugs, especially the role of corticosteroids (dexamethasone), antibiotics (azithromycin), anti-thrombotic drugs, blood derivates therapies and alternative therapies currently used against COVID-19. Also, we listed the main results of clinical trials of new therapies presented by Recommended Panel Treatment Guidelines [NIAID-RML (USA)]. We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We used 302 articles from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, immunomodulators, parasiticides, antiviral, antimalarial, anti-thrombotic and anti-cytokine, antiinflammatory, Reumathological drugs, inhibitors of cell-receptors, antibiotics, blood derivates therapies and alternative therapies, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that despite there is no treatment or drugs against the COVID-19, a combined therapy can help and mitigate the effects of the disease, helping the immune system to combat the virus.  

scholarly journals Diagnostic of COVID-19: Chest Computer Tomography or RT-PCR?

2020 ◽  
Vol 3 (2) ◽  
pp. 177-183
Author(s):  
ISI-SENAI-CIMATEC Group
Keyword(s):  
Standard Method ◽  
Computer Tomography ◽  
Gold Standard ◽  
Clinical Investigation ◽  
Diagnostic Methods ◽  
World Health ◽  
Rt Pcr ◽  
Medical Subject Headings ◽  
Gold Standard Method ◽  
Novel Coronavirus

In this review article, we presented a gold-standard method to detect the SARS-CoV-2, the novel virus that is causing the COVID-19 outbreak, and the use of a computer tomography (CT) method to detect the complications of the disease. We showed the controversial analysis about which method is the best to detect the disease earlier due to the COVID-19 complications. We searched the articles in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We reviewed 96 articles and used 45 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, RT-PCR, computer tomography (CT), diagnostic methods, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that chest CT plays an important role in the timely detection of lung infection abnormalities in the early phase of COVID-19 infection. However, the RT-PCR is the gold standard method to detect SARS-CoV-2.  

scholarly journals Psychosocial Distress of Patients with Psoriasis: Protocol for an Assessment of Care Needs and the Development of a Supportive Intervention (Preprint)

2017 ◽  
Author(s):  
Jördis Maria Zill ◽  
Jörg Dirmaier ◽  
Matthias Augustin ◽  
Sarah Dwinger ◽  
Eva Christalle ◽  
...  
Keyword(s):  
Systematic Review ◽  
Supportive Care ◽  
Psychosocial Support ◽  
Meta Analysis ◽  
Phase 1 ◽  
Psychosocial Distress ◽  
Supportive Care Needs ◽  
Phase 2 ◽  
Care Needs ◽  
Supportive Intervention

BACKGROUND Psoriasis is a chronic inflammatory disease that is often associated with a number of somatic and mental comorbidity. Patients with psoriasis show an increased risk of depression and (social) anxiety. OBJECTIVE The aims of this study are 1) to explore the psychosocial distress of patients with psoriasis and to assess their care needs; and 2) to develop a supportive intervention based on the prior results. METHODS A multi-stage design with four phases combining quantitative and qualitative methodology will be used and conducted in two centers. 1) A scoping review and focus groups will be used to design a questionnaire to assess the psychosocial distress and care needs of the patients. 2) The questionnaire developed in phase 1 will be used in a cross-sectional survey to assess the extent of psychosocial distress and supportive care needs in 400 patients with psoriasis. 3) A systematic review and meta-analysis will be conducted to identify psychosocial and psychoeducational interventions for patients with psoriasis and to describe their effectiveness. 4) Based on the results of the phases 2 and 3 a manualized supportive intervention will be developed and the feasibility and acceptance of the intervention will be assessed. RESULTS Currently, phase 1 of the project has been completed and the recruitment for phase 2 has been started. The systematic review and meta-analysis of phase 3 are conducted simultaneously to phase 2 and results are expected soon. Phase 4 has not been started yet. CONCLUSIONS The expected results of this study will show the extent of psychosocial distress of patients with psoriasis in Germany and supplement previous research with findings about the supportive care needs of this patient group. Moreover, the developed intervention will help to address the psychosocial support needs of patients with psoriasis. Research shows that psychosocial support is strongly needed.

Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19)

2020 ◽  
Vol 48 (04) ◽  
pp. 763-777 ◽  
Author(s):  
Leyin Zhang ◽  
Jieru Yu ◽  
Yiwen Zhou ◽  
Minhe Shen ◽  
Leitao Sun
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Viral Entry ◽  
Meta Analysis ◽  
Chinese Herb ◽  
Chinese Herbs ◽  
World Health ◽  
Symptom Improvement ◽  
Novel Coronavirus ◽  
Health Organization

The outbreak caused by COVID-19 is causing a major challenge to clinical management and a worldwide threat to public health. So far, there is no specific anti-coronavirus therapy approved for the treatment of COVID-19. Recently, as the efficacy and safety of traditional Chinese medicine (TCM) is widely acknowledged, it has been brought to a crucial status by the public, governments, and World Health Organization (WHO). For a better popularization of TCM, governments have made several advances in regulations and policies for treatment and measures of novel coronavirus pneumonia (NCP). Therefore, on the basis of epidemiology and virology information, we reviewed relevant meta-analysis and clinical studies of anti-coronavirus therapeutics by TCM, in the aspect of mortality, symptom improvement, duration and dosage of corticosteroid, incidence of complications and the like. In addition, we also summarized preclinical rationale for anti-coronavirus activity by TCM in terms of virion assembly and release, as well as viral entry and replication, which could be a useful contribution for figuring out effective Chinese herbal medicine (CHM) for coronavirus, including ingredients from single monomeric compounds, Chinese herbs, Chinese herb extracts and Chinese herb formulas, or potential targets for medicine. We would like to see these relevant studies, ranging from basic researches to clinical application, could provide some idea on effects of CHM to combat COVID-19 or other coronaviruses, and also offer new thinking for the exploration of therapeutic strategies under the guidance of TCM.

scholarly journals Spatiotemporal distribution of COVID-19 during the first 7 months of the epidemic in Vietnam

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Toshie Manabe ◽  
Dung Phan ◽  
Yasuhiro Nohara ◽  
Dan Kambayashi ◽  
Thang Huu Nguyen ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Phase 1 ◽  
Age Distribution ◽  
Emerging Infectious Diseases ◽  
Spatial Cluster ◽  
Spatiotemporal Distribution ◽  
Control Measures ◽  
World Health ◽  
Phase 2 ◽  
Epidemic Wave

Abstract Background Understanding the spatiotemporal distribution of emerging infectious diseases is crucial for implementation of control measures. In the first 7 months from the occurrence of COVID-19 pandemic, Vietnam has documented comparatively few cases of COVID-19. Understanding the spatiotemporal distribution of these cases may contribute to development of global countermeasures. Methods We assessed the spatiotemporal distribution of COVID-19 from 23 January to 31 July 2020 in Vietnam. Data were collected from reports of the World Health Organization, the Vietnam Ministry of Health, and related websites. Temporal distribution was assessed via the transmission classification (local or quarantined cases). Geographical distribution was assessed via the number of cases in each province along with their timelines. The most likely disease clusters with elevated incidence were assessed via calculation of the relative risk (RR). Results Among 544 observed cases of COVID-19, the median age was 35 years, 54.8% were men, and 50.9% were diagnosed during quarantine. During the observation period, there were four phases: Phase 1, COVID-19 cases occurred sporadically in January and February 2020; Phase 2, an epidemic wave occurred from the 1st week of March to the middle of April (Wave 1); Phase 3, only quarantining cases were involved; and Phase 4, a second epidemic wave began on July 25th, 2020 (Wave 2). A spatial cluster in Phase 1 was detected in Vinh Phuc Province (RR, 38.052). In Phase 2, primary spatial clusters were identified in the areas of Hanoi and Ha Nam Province (RR, 6.357). In Phase 4, a spatial cluster was detected in Da Nang, a popular coastal tourist destination (RR, 70.401). Conclusions Spatial disease clustering of COVID-19 in Vietnam was associated with large cities, tourist destinations, people’s mobility, and the occurrence of nosocomial infections. Past experiences with outbreaks of emerging infectious diseases led to quick implementation of governmental countermeasures against COVID-19 and a general acceptance of these measures by the population. The behaviors of the population and the government, as well as the country’s age distribution, may have contributed to the low incidence and small number of severe COVID-19 cases.

scholarly journals Identifying the World Health Organization’s fifth moment for hand hygiene: Infection prevention in the operating room

2019 ◽  
Vol 21 (1) ◽  
pp. 28-34
Author(s):  
Fiona Smith ◽  
Karen Lee ◽  
Eleanor Binnie-McLeod ◽  
Mark Higgins ◽  
Elizabeth Irvine ◽  
...  
Keyword(s):  
Hand Hygiene ◽  
Operating Room ◽  
Direct Contact ◽  
Phase 1 ◽  
World Health ◽  
Phase 2 ◽  
Frontline Staff ◽  
The World ◽  
Hygiene Compliance ◽  
Health Organization

Background: The World Health Organization have designed the fifth of their ‘5 moments’ for hand hygiene to account for microbial transfer from patients to equipment in a narrow area around that patient, known as the patient zone. The study was prompted by emerging local confusion about application of the patient zone in the operating room (OR). Aim/Objectives: In two phases, we aimed to create a ‘5 moments’ style poster displaying an OR patient zone: phase 1, quantify equipment, in direct contact with the patient and, touched by non-scrubbed staff immediately after touching the patient; and phase 2, categorise equipment identified in phase 1 into patient zone and healthcare zone. An objective is to produce a ‘5 moments’ poster for the OR. Methods: The first phase used non-participant direct overt observation. In phase 2, phase 1 data were collaboratively assigned to patient zone or healthcare zone. Photography and graphic design were used to produce the OR ‘5 moments’ poster. Results: In 11 full-length surgeries, 20 pieces of equipment were in direct contact with the patient and 57 pieces of equipment were touched. In phase 2, a ‘5 moments’ poster showing an OR patient zone was designed. Discussion: Content of the patient zone was identified and displayed in a novel resource. Having shared understanding of the patient zone has potential to sustain hand hygiene compliance and equipment cleaning in the OR. Conclusion: Limitations in methods were balanced by collaboration with frontline staff. The study has been used as a teaching tool in the OR and similar settings.

Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 20521-20521 ◽  
Author(s):  
L. P. Hartner ◽  
L. Rosen ◽  
M. Hensley ◽  
D. Mendelson ◽  
A. P. Staddon ◽  
...  
Keyword(s):  
Clinical Investigation ◽  
Phase 1 ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Apoptotic Protein ◽  
Three Phase ◽  
Phase 2 Study ◽  
Lost To Follow Up

20521 Background: ARQ 501 selectively induces apoptosis in cancer cells by inducing a rapid and sustained increase of the pro- apoptotic protein E2F-1. ARQ 501 has been studied in three phase 1 studies, demonstrating acceptable toxicity and encouraging signs of efficacy. A 54 y/o female with metastatic LMS who failed 7 previous therapies achieved a prolonged PR on ARQ 501 monotherapy. This was consistent with preclinical data, where induction of E2F-1 and corresponding efficacy in human leiomyosarcoma xenografts was observed. Methods: A phase 2 study in adult LMS patients (>3 prior systemic therapies) was initiated to assess ORR, TTP and further characterize the safety of ARQ 501. ORR included CR, PR and SD=4 mo. Four week cycles (ARQ 501 450mg/m2) were repeated until progression, unacceptable toxicity, or another discontinuation criterion. Results: 49 patients were enrolled and 45 received ARQ 501. Data is available for 43 patients (4M/39F, median age, 54). Of the 43, 10 did not reach a protocol defined tumor assessment (4 deaths, 5 PD and 1 lost to follow-up prior to week 8), 19 have been assessed for response per RECIST at eight weeks (7 SD of 8–28+ weeks, 1 PR, 11 PD) and 14 active patients yet to reach first tumor assessment. The most common AEs were: anemia (68%, 21%=G3), hyperbilirubinemia (35%, 6%=G3), fatigue (35%, 0%=G3), nausea (30%, 0%=G3), constipation (24%), hemolysis (21%, 6%=G3), dyspnea (21%), and vomiting (21%). One treatment related death was reported in a 47 y/o Asian male with severe hemolysis following a single infusion of ARQ 501 at 450 mg/m2. The pt was hospitalized, but severe hemolysis led to acute renal failure and the patient expired after 4 days. Conclusions: ARQ 501 was administered to 45 patients with advanced, recurrent or persistent leiomyosarcoma. Several patients have achieved some clinical benefit (1 PR, 3 prolonged SD), further analysis of efficacy data is warranted prior to additional clinical investigation. No significant financial relationships to disclose.

scholarly journals The Radiological Images and the Diagnostic of COVID-19

2020 ◽  
Vol 3 (1) ◽  
pp. 79-90
Author(s):  
Cesar Augusto de Araújo Neto
Keyword(s):  
Gold Standard ◽  
Clinical Investigation ◽  
World Health ◽  
Imaging Method ◽  
Minimal Risk ◽  
Rt Pcr ◽  
Gold Standard Method ◽  
X Ray ◽  
Inflammatory Phase ◽  
Novel Coronavirus

The gold-standard method to identify the presence of COVID-19 is the RT-PCR. However, the imaging diagnostic has been requested when there is suspicion of disease’s presence and/or the inflammatory phase of the disease begins. Ths artices described the most common manifestations and patterns of lung abnormality on computed X-Ray (CXR), computer tomography (CT) and Ultrasound of the chest in COVID-19. Notwithstanding the RT-PCR is the gold-standard diagnostic method for COVID-19, the CT has been shown an essential tool to identify pneumonia and the complications of COVID-19 in a patient. This review article aimed to summarize the radiological findings of COVID-19 researches for the following three principal areas: (1) radiological performance in the detection of COVID-19; (2) radiological role in the diagnosis of COVID-19; and (3) radiological function in the monitoring of COVID-19. We searched the articles in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Exerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews and original articles in this order. We reviewed 121 articles and used 57 for this paper from March to May 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-Sars-2, COVID-19, corona virus, coronaviruses, diagnostic, radiology, imaging, computed tomography, chest, CT, X-Ray, with the tools MeSH (Medical Subject Headings), AND, OR, and characters [,“,; /., to ensure the best review topics. We concluded that the imaging method to detect the features of COVID-19 plays an important role in the diagnosis and follow up of the patient with COVID-19 pneumonia. Despite CT has a better sensitivity when compared to CRX and ultrasound, the portable CRX and portable ultrasound could be a new tool with minimal risk of contamination and with good sensitivity.

Sign in / Sign up

Export Citation Format

Share Document